ACAA2 and Alzheimer disease: Further findings included broader upregulation of lipid catabolism and mitochondrial metabolism, including mitochondrial enzymes (e.g., Acsf2, Acadl, and Acaa2) with NVS‐PAK1‐1 treatment across all cohorts suggesting a metabolic rebalancing toward fatty acid oxidation and mitochondrial efficiency may help mitigate metabolic dysfunction common in AD, though the direct connection to PAK1 inhibition is uncertain.